title: [The emergency treatment of supraventricular tachyarrhythmias: the efficacy and safety of intravenous propafenone].
abstract: One hundred patients, admitted to the Emergency Unit for paroxysmal supraventricular tachycardia (SVT) with 1:1 AV conduction, atrial fibrillation (af) and flutter (AF) of recent onset (less than 72 hours) were treated with intravenous propafenone (P). The drug was administered at the dose of 70 mg over 5 min, repeated after 10 min if sinus rhythm (SR) was not restored and eventually followed by continuous infusion (0.35-0.50 mg/min) until conversion to SR or during the next 48 hours. Exclusion criteria were ventricular rate < 100/min, R-R intervals > 1 s, clinical signs of heart failure or asthma. Termination of SVT within 30 min was obtained in 94% of the patients, while reversion to SR occurred in 79% with af and in 55% with AF. For af and AF conversion was achieved within 30 min in 49% of overall responders (R), between 30 min and 6 hours in 27% and between 6 hours and 48 hours in 24%. The efficacy of P was significantly influenced by the duration of arrhythmia and left atrial size, measured by 2D-echocardiography. On the contrary, no difference was observed between R and non-R in mean age and in the percentage of primary or relapsing arrhythmias. Adverse effects were encountered in 7 patients: in 1 case worsened arrhythmia and in 6 patients, with long-lasting arrhythmias, congestive heart failure. Neither conduction disturbance nor extra-cardiac complications occurred. In conclusion, P provides effective and safe treatment for paroxysmal atrial tachyarrhythmias, so that it can be considered among the drugs of first choice even in non-intensive care units.
authors.affiliation: Servizio di Cardiologia, Ospedale di Saronno, VA.
authors.forename: G
authors.initials: G
authors.lastname: Tisi
authors.forename: P
authors.initials: P
authors.lastname: Annoni
authors.forename: R
authors.initials: R
authors.lastname: Baroffio
authors.forename: L
authors.initials: L
authors.lastname: Cazzaniga
authors.forename: C
authors.initials: C
authors.lastname: Ciaramella
authors.forename: F
authors.initials: F
authors.lastname: Guzzini
authors.forename: A
authors.initials: A
authors.lastname: Maestroni
authors.forename: M
authors.initials: M
authors.lastname: Bossi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016009:Chi-Square Distribution; D004341:Drug Evaluation; D004630:Emergencies; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011405:Propafenone / Q000008:administration & dosage* / Q000009:adverse effects; D012008:Recurrence; D013617:Tachycardia, Supraventricular / Q000188:drug therapy* / Q000453:epidemiology; D013997:Time Factors
chemical_list: D011405:Propafenone
vernacular_title: II trattamento d'emergenza delle tachiaritmie sopraventricolari: efficacia e sicurezza del propafenone endovena.